Stifel Financial Corp Purchases New Holdings in Emergent BioSolutions Inc. (NYSE:EBS)

Stifel Financial Corp purchased a new stake in Emergent BioSolutions Inc. (NYSE:EBS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 11,460 shares of the biopharmaceutical company’s stock, valued at approximately $96,000.

A number of other hedge funds also recently modified their holdings of the company. Meeder Asset Management Inc. bought a new stake in shares of Emergent BioSolutions during the second quarter valued at approximately $41,000. Verus Capital Partners LLC acquired a new stake in Emergent BioSolutions during the second quarter worth $68,000. FORA Capital LLC bought a new stake in Emergent BioSolutions in the 3rd quarter valued at $103,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of Emergent BioSolutions in the 2nd quarter valued at $93,000. Finally, Morse Asset Management Inc bought a new position in shares of Emergent BioSolutions during the 2nd quarter worth about $97,000. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Trading Up 11.9 %

Shares of EBS stock opened at $9.25 on Tuesday. The company has a market capitalization of $501.20 million, a P/E ratio of -2.26 and a beta of 1.59. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $15.10. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. The firm has a 50-day moving average price of $9.19 and a 200 day moving average price of $8.91.

Analyst Ratings Changes

A number of research firms recently weighed in on EBS. HC Wainwright started coverage on shares of Emergent BioSolutions in a research note on Monday. They issued a “buy” rating and a $15.00 target price on the stock. StockNews.com lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Saturday. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Finally, Benchmark boosted their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, November 7th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.